Pathstone Holdings
BCYC

Pathstone Holdings’s Bicycle Therapeutics BCYC Stock Holding History

Pathstone Holdings’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,228
Closed -$231K – 2309
2024
Q3 		$231K Buy
+10,228
New +$236K ﹤0.01% 2101

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Pathstone Holdings's BCYC Position: Q4 2024 in Review

Pathstone Holdings sold out of Bicycle Therapeutics (BCYC) in Q4 2024, closing a stake of 10,228 shares — an estimated $231K sold.

Pathstone Holdings first reported a position in BCYC in Q3 2024 and held it in 1 quarter. The position peaked at $231K in Q3 2024. 97 funds tracked by Wall St. Rank hold BCYC as of Q4 2024.

  • Pathstone Holdings reported no remaining Bicycle Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Pathstone Holdings sold 10,228 Bicycle Therapeutics shares in Q4 2024, an estimated $231K.
  • Pathstone Holdings first reported a position in Bicycle Therapeutics in Q3 2024 and held it in 1 quarter.
  • Pathstone Holdings's Bicycle Therapeutics position peaked at $231K in Q3 2024.
  • 97 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q4 2024.

Based on Pathstone Holdings's 13F filing for Q4 2024, filed 14 Feb 2025.